期刊
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
卷 67, 期 10, 页码 2474-2478出版社
OXFORD UNIV PRESS
DOI: 10.1093/jac/dks216
关键词
HIV; immune activation; maraviroc; darunavir; CCR5; CXCR4; naive T cells
资金
- Abbott
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Tibotec (Johnson Johnson)
- GlaxoSmithKline
- Merck Sharp Dohme
- ViiV Healthcare
- Gilead Sciences
- Roche
- Pfizer
- Virco (Johnson Johnson)
Patients treated with maraviroc frequently show high CD4 T cell increases. The aim of this study was to detail the characteristics of maraviroc-induced immune recovery. We studied T cell subsets from frozen peripheral blood mononuclear cells of patients treated with raltegravir, etravirine and either maraviroc (REM, n24) or darunavir/ritonavir (RED, n17). The two groups showed a similar decrease in activated CD4 and CD8 T cells. A greater loss of naive CD4 T cells and a reduction in cells expressing CXCR4 were observed in REM patients, while RED patients showed a greater loss of cells expressing CCR5. Our findings do not support a role for reduction in activated T cell subsets to explain the greater maraviroc-induced immune recovery. Reduction in CXCR4CD4 and higher expression of CCR5CD4 T cells might represent a potential protection from non-R5 tropic viral strain overgrowth.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据